Search Result

Results for "

th17+cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA Carboxylase (1) Apoptosis (1) Aurora Kinase (2) Biochemical Assay Reagents (4) CCR (1) Complement System (1) Drug Derivative (1) Environmental Pollutants (1) Epigenetic Reader Domain (4) ERK (1) FGFR (1) Fluorescent Dye (1) Glucose-6-Phosphate Isomerase (GPI) (2) GPR39 (1) Histone Acetyltransferase (1) IFNAR (1) Influenza Virus (1) Interleukin Related (17) Isotope-Labeled Compounds (1) Itk (1) JAK (8) LPL Receptor (2) Mitosis (2) Na+/K+ ATPase (4) NF-κB (3) NO Synthase (1) Notch (2) p38 MAPK (1) PKC (1) PPAR (1) Reactive Oxygen Species (ROS) (1) Reference Standards (3) ROR (17) STAT (10) Toll-like Receptor (TLR) (3) VEGFR (1) VISTA (1) Wnt (1)
By Research Areas:	Cancer (11) Cardiovascular Disease (3) Infection (1) Inflammation/Immunology (54) Metabolic Disease (2) Neurological Disease (1)
Oligonucleotides:	Antisense Oligonucleotides (2)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100754

Ritlecitinib 5+ Cited Publications PF-06651600	JAK Interleukin Related STAT	Inflammation/Immunology
Ritlecitinib (PF-06651600) is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC₅₀=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC₅₀ >10 μ M). Ritlecitinib rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .

HY-Y0344D

*Sodium chloride, for cell* culture** 3 Publications Verification Halite, for cell culture	Environmental Pollutants Biochemical Assay Reagents Interleukin Related Na+/K+ ATPase	Inflammation/Immunology Cancer
Sodium chloride, for cell culture is an orally active salt. Sodium chloride, for cell culture induces the expression of ATP1A1. Sodium chloride, for cell culture induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, for cell culture enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, for cell culture drives autoimmune disease by the induction of pathogenic Th17 cells .

HY-15826

SGC-CBP30 Maximum Cited Publications 20 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Inflammation/Immunology Cancer
SGC-CBP30, a chemical probe, is a potent and highly selective CBP/p300 bromodomain (K_ds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .

HY-125801

3-Oxo-5β-cholanoic acid 1 Publications Verification Dehydrolithocholic acid; 3-oxoLCA	ROR	Inflammation/Immunology
3-Oxo-5β-cholanoic acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of *TH17* cells by directly binding to the key transcription factor RORγt (K_d=1.13 μM) .

HY-12776

GSK805 5 Publications Verification	ROR	Inflammation/Immunology
GSK805 is an orally active and CNS penetrant RORγt inhibitor. GSK805 inhibits RORγ and Th17 cells differentiation with pIC₅₀ values of 8.4 and >8.2. GSK805 inhibits the function of Th17 cells. GSK805 can be used for the research of immunity .

HY-Y0344J

Sodium chloride, for molecular biology 3 Publications Verification Halite, for molecular biology	Biochemical Assay Reagents Na+/K+ ATPase Interleukin Related	Inflammation/Immunology Cancer
Sodium chloride is an orally active salt. Sodium chloride induces the expression of ATP1A1. Sodium chloride induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride drives autoimmune disease by the induction of pathogenic Th17 cells .

HY-P99256

Tildrakizumab SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody	Interleukin Related	Inflammation/Immunology Cancer
Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (K_d: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .

HY-16734A

Amiselimod hydrochloride MT-1303 hydrochloride	LPL Receptor	Cardiovascular Disease Inflammation/Immunology
Amiselimod (MT-1303) hydrochloride is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod hydrochloride is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod hydrochloride inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod hydrochloride inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimod hydrochloride is promising for research of autoimmune diseases .

HY-Y0344I

Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al 3 Publications Verification Halite, meets analytical specification of Ph. Eur. BP USP	Biochemical Assay Reagents Na+/K+ ATPase Interleukin Related	Inflammation/Immunology Cancer
Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt is an orally active salt. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt induces the expression of ATP1A1. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt drives autoimmune disease by the induction of pathogenic Th17 cells .

HY-100754C

Ritlecitinib tosylate 5+ Cited Publications PF-06651600 tosylate	JAK Interleukin Related STAT	Inflammation/Immunology
Ritlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC₅₀=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC₅₀ >10 μ M). Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .

HY-113238A

Lithocholic acid 3-sulfate disodium Sulfolithocholic acid disodium; LCAS disodium	GPR39 ROR	Metabolic Disease Inflammation/Immunology
Lithocholic acid 3-sulfate disodium is a GPR39 agonist, with EC₅₀ values of 41 μM and 42.4 μM in M39-20 and hGPR39-2 cells, respectively, in the absence of Zn ²⁺, and 0.88 μM and 0.97 μM in the presence of Zn ²⁺. Lithocholic acid 3-sulfate disodium acts as a RORγt ligand. Lithocholic acid 3-sulfate disodium stimulates the GPR39 receptor to initiate intracellular calcium signaling, independent of the Zn ²⁺-binding sites H17 and H19. LCA-3-S selectively inhibits Th17 cell differentiation by targeting RORγt. Lithocholic acid 3-sulfate disodium can be used in the research of cholestatic liver diseases .

HY-120000

MS402 2 Publications Verification	Epigenetic Reader Domain	Inflammation/Immunology Cancer
MS402 is a BD1-selective BET BrD inhibitor with K_is of 77 nM, 718 nM, 110 nM, 200 nM, 83 nM, and 240 nM for BRD4(BD1), BRD4(BD2), BRD3(BD1), BRD3(BD2), BRD2(BD1) and BRD2(BD2), respectively. MS402 blocks Th17 cell differentiation and ameliorates colitis in mice .

HY-W011220

Ciglitazone 1 Publications Verification ADD-3878; U-63287	PPAR	Cardiovascular Disease Cancer
Ciglitazone is a potent and selective PPARγ agonist (EC₅₀=3 μM). Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone induces apoptosis accompanied by activation of p38 MAPK and nuclear translocation of apoptosis inducing factor (AIF) in opossum kidney (OK) renal epithelial cells .

HY-126037

(±)-ML 209 1 Publications Verification	ROR	Inflammation/Immunology
(±)-ML 209 (compound 4n), a diphenylpropanamide, is a retinoic acid-related orphan receptor RORγ antagonist with an IC₅₀ of 1.1 μM. (±)-ML 209 inhibits RORγt transcriptional activity with an IC₅₀ of 300 nM in HEK293t cells. (±)-ML 209 inhibits the transcriptional activity of RORγt, but not RORα in cells. (±)-ML 209 selectively inhibits murine Th17 cell differentiation without affecting the differentiation of naïve CD4 ⁺ T cells into other lineages, including Th1 and regulatory T cells .

HY-P990145

Anti-Mouse VISTA Antibody (13F3)	VISTA	Inflammation/Immunology Cancer
Anti-Mouse VISTA Antibody (13F3) is an anti-mouse VISTA IgG monoclonal antibody. Anti-Mouse VISTA Antibody (13F3) can reverse the immunosuppressive effect of VISTA by blocking its binding to ligands such as VSIG3. Anti-Mouse VISTA Antibody (13F3) exacerbates pulmonary fibrosis (PF) by promoting Th17 cell differentiation. Anti-Mouse VISTA Antibody (13F3) can be used for research on cancer such as breast cancer and PF .

HY-126328

PKC-theta inhibitor 1	PKC Interleukin Related	Inflammation/Immunology
PKC-theta inhibitor 1 is an orally active and selective ATP-competitive inhibitor of Protein Kinase Cθ (PKCθ), with a K_i value of 6 nM. PKC-theta inhibitor 1 inhibits T-cell-mediated inflammatory responses by suppressing the release of proinflammatory cytokines (IL-2 IC₅₀ = 0.21 μM in anti-CD3/CD28-stimulated PBMCs; *IL-17* IC₅₀ = 1 μM in CD3/CD28-stimulated Th17 cells) PKC-theta inhibitor 1 significantly reduces symptoms in mice with ongoing experimental autoimmune encephalomyelitis (EAE). PKC-theta inhibitor 1 can be used for the study of T-cell-mediated inflammatory diseases such as multiple sclerosis .

HY-155487

JTE-151	ROR	Neurological Disease Inflammation/Immunology
JTE-151 is a RORγ inhibitor, which can suppress overactive immune response through inhibition of RORγ related to the activation of Th17 cells, making JTE-151 possible to be used in autoimmune disease research .

HY-P10109

G6PI 325-339 (human)	Glucose-6-Phosphate Isomerase (GPI)	Inflammation/Immunology
G6PI 325-339 (human) is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms .

HY-138115

7ß,27-Dihydroxycholesterol 7β, 27-OHC	ROR	Inflammation/Immunology
7ß,27-Dihydroxycholesterol (7β, 27-OHC) is a potent and selective activator of RORγt (K_i=120 nM). 7ß,27-Dihydroxycholesterol promotes the differentiation of mouse and human CD4 ⁺ Th17 cells. 7ß,27-Dihydroxycholesterol also increases the production of IL-17 depended on CYP27A1 .

HY-174903

ITK-IN-6	Itk	Inflammation/Immunology
ITK-IN-6 is a highly potent and selective ITK inhibitor (K_d = 387 nM). ITK-IN-6 directly binds to the ITK kinase domain. ITK-IN-6 blocks the release of pro-inflammatory cytokines and the activation and differentiation of Th2 and Th17 cells. ITK-IN-6 improves asthma progression by reducing inflammatory cell infiltration, mucus and IgE production. ITK-IN-6 significantly inhibits airway inflammation and is used in asthma research .

HY-P990796

Anti-Mouse IL-2 Antibody (S4B6-1)	Interleukin Related	Inflammation/Immunology Cancer
Anti-Mouse IL-2 Antibody (S4B6-1) is an anti-mouse IL-2 IgG2a monoclonal antibody. Anti-Mouse IL-2 Antibody (S4B6-1) can reduce CD4 ⁺ T cells and increase Tregs. Anti-Mouse IL-2 Antibody (S4B6-1) can induce Th17 cell differentiation. Anti-Mouse IL-2 Antibody (S4B6-1) can be used for research on cancer such as melanoma. The recommend isotype control of Anti-Mouse IL-2 Antibody (S4B6-1): Rat IgG2a kappa, Isotype Control (HY-P990679) .

HY-156466

QL-1200186	STAT Interleukin Related IFNAR	Inflammation/Immunology
QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase TYK2 pseudokinase domain JH2 (IC₅₀=0.06 nM, TYK2 JH2), with 164-fold selectivity over TYK1 JH2 (IC₅₀=9.85 nM，TYK1 JH2). QL-1200186 first stabilizes the TYK2 JH2 conformation, inhibits the activity of the JH1 catalytic domain, and blocks the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE) .

HY-120785

SR1555	ROR	Inflammation/Immunology
SR1555 is a specific retinoic acid receptor-related orphan nuclear receptor γ (RORγ) inverse agonist with an IC₅₀ value of 1 μM. SR1555 not only inhibits TH17 cell development and function but also increases the frequency of T regulatory cells, as well as inhibits the expression of IL-17. SR1555 can be used for researching autoimmune diseases .

HY-179537

CKBA	Acetyl-CoA Carboxylase Drug Derivative	Inflammation/Immunology
CKBA, a derivative of AKBA (HY-N0892) is an inhibitor of acetyl-CoA carboxylase 1 (ACC1), with an IC₅₀ of 5.02 μM. CKBA inhibits the differentiation of Th17 cells and has IC₅₀ values of 3.28 μM for mouse cells and 3.61 μM for human cells. CKBA ointment significantly alleviates psoriasis-like inflammation in mice. CKBA can be used for the study of psoriasis .

HY-Y0344H

Sodium chloride, United States Pharmacopeia (USP) Reference Standard Halite (Pharmaceutical primary standard, USP)	Biochemical Assay Reagents Na+/K+ ATPase Interleukin Related	Inflammation/Immunology Cancer
Sodium chloride, United States Pharmacopeia (USP) Reference Standard is an orally active salt. Sodium chloride, United States Pharmacopeia (USP) Reference Standard induces the expression of ATP1A1. Sodium chloride, for cell culture induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, United States Pharmacopeia (USP) Reference Standard enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, United States Pharmacopeia (USP) Reference Standard drives autoimmune disease by the induction of pathogenic Th17 cells .

HY-145491

Resolvin D5	ERK NF-κB CCR	Inflammation/Immunology
Resolvin D5 is an anti-inflammatory and analgesic agent produced in M2 macrophages. Resolvin D5 alleviates Paclitaxel (HY-B0015)-induced mechanical allodynia and inflammatory pain by activating the GPR32 receptor, with gender specificity (effective only in male mice) and independence from TRPV1 or TRPA1 channels. Resolvin D5 attenuates LPS-induced ERK phosphorylation and NF-κB nuclear translocation, downregulates proinflammatory mediators such as IL-6 and CCL5, inhibits Th17 cell differentiation and osteoclastogenesis, promotes regulatory T cell differentiation, and shows no cytotoxicity to human monocytes. The level of Resolvin D5 is elevated in arthritic SKG mice, but Resolvin D5 has no effect on dendritic cell differentiation or M1 macrophage polarization, nor does it prevent ZyA-induced arthritis progression. Resolvin D5 is suitable for research related to chemotherapy-induced peripheral neuropathy, inflammatory pain and rheumatoid arthritis .

HY-120225

NJK14047	p38 MAPK	Inflammation/Immunology
NJK14047 inhibits p38 MAPK and the differentation of naive T-cells to Th1 and Th17 cells. NJK14047 ameliorates the collage-induced rheumatoid arthritis and Imiquimod (HY-B0180)-induced psoriasis in mice .

HY-W130878

4-Octylphenol	Complement System Toll-like Receptor (TLR) NF-κB	Inflammation/Immunology
4-Octylphenol is a hormone disruptor that has gender-specific effects on male reproductive cells, significantly reducing the mitotic index and the number of spermatogonia. 4-Octylphenol can cause inflammatory damage to fish gills by activating the complement system through the C3a/C3aR axis and the C5a/C5aR1 axis, this leads to complement activation and causes immune suppression due to the imbalance between Th1/Th2 cells and regulatory T cells (Treg)/Th17 cells, as well as inflammatory damage via the Toll-like receptor 7 (Toll-like Receptor (TLR))/IκBα/NF-κB pathway .

HY-160040

Cobitolimod	Toll-like Receptor (TLR)	Inflammation/Immunology
Cobitolimod is a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory activity. Cobitolimod suppresses Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .

HY-162490

TF-S14	ROR	Inflammation/Immunology
TF-S14 is a reverse agonist of RORγt. TF-S14 reduces Th17 cell-associated cytokine production, including IL-17A, IL-21, and IL-22 by binding to and inhibiting RORγt activity. TF-S14 can be used in the study of autoimmune diseases and rejection in allotransplantation .

HY-P991274

BMS-986010	Interleukin Related	Inflammation/Immunology
BMS-986010 is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). BMS-986010 reduces IL-23-induced STAT3 phosphorylation and inhibits Th17 cell differentiation and the release of proinflammatory cytokines (such as IL-17 and TNF-α). BMS-986010 is promising for research of autoimmune diseases such as psoriasis and Crohn's disease .

HY-164454

AJI-100	Aurora Kinase STAT JAK Mitosis	Inflammation/Immunology
AJI-100 is a dual-target inhibitor of Aurora kinase A and JAK2 with IC₅₀ values of 12.7 nM and 18.5 nM, respectively. AJI-100 directly blocks Aurora kinase A to inhibit T cell mitosis and cell polarity, and inhibits JAK2 activation to inhibit STAT3 phosphorylation, thereby reducing the differentiation of TH1 and TH17 cells. AJI-100 can be used in studies on regulating immune responses and preventing graft-versus-host disease (GVHD) .

HY-16734

Amiselimod MT-1303	LPL Receptor	Cardiovascular Disease Inflammation/Immunology
Amiselimod (MT-1303) is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimodis promising for research of autoimmune diseases .

HY-100754A

Ritlecitinib malonate PF-06651600 malonate	JAK Interleukin Related STAT	Inflammation/Immunology
Ritlecitinib (PF-06651600) malonate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC₅₀=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC₅₀ >10 μ M). Ritlecitinib malonate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib malonate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .

HY-143885

JAK1/TYK2-IN-3	JAK	Inflammation/Immunology
JAK1/TYK2-IN-3 is a potent, selective and orally active dual TYK2/JAK1 inhibitor with IC₅₀ values of 6 and 37 nM, respectively. JAK1/TYK2-IN-3 also shows selectively relative to JAK2 (IC₅₀=140 nM) and JAK3 (IC₅₀=362 nM). JAK1/TYK2-IN-3 shows anti-inflammatory effect by regulating the expression of related TYK2/JAK1-regulated genes, as well as the formation of Th1, Th2, and Th17 cells .

HY-N0976

1,11b-Dihydro-11b-hydroxymedicarpin 11b-Hydroxy-11b,1-dihydromedicarpin	Interleukin Related Wnt	Inflammation/Immunology
1,11b-Dihydro-11b-hydroxymedicarpin (11b-Hydroxy-11b,1-dihydromedicarpin) is a pterocarpan from Ononis viscosa subsp. breviflora is a Medicarpin derivative . Medicarpin, a natural pterocarpan, heals cortical bone defect by activation of Notch and Wnt canonical signaling pathways . Medicarpin prevents arthritis in post-menopausal conditions by arresting the expansion of TH17 cells and pro-inflammatory cytokines. Medicarpin down-regulates pro-inflammatory cytokines like TNF-α, IL-6 and IL-17A, while up-regulates anti-inflammatory cytokine IL-10 in arthritis (CIA) model of mice .

HY-176535

KB-0118 BBC0115	Epigenetic Reader Domain Interleukin Related STAT	Inflammation/Immunology
KB-0118 (BBC0115) is an orally active BET bromodomain inhibitor. KB-0118 selective binds to BRD2 and BRD4 over BRD3, with K_d values of 36.7 μM for BRD2 BD1 and 47.4 μM for BRD4 BD1. KB-0118 inhibits pro-inflammatory cytokines, including TNF, IL-1β, and IL-23a and selectively suppresses Th17 cell differentiation. KB-0118 modulates Th17-driven inflammation occurs through epigenetic suppression of BRD4, confirmed by downregulation of STAT3 and BRD4 target genes. KB-0118 has immunomodulatory effects in inflammatory bowel disease (IBD) model.

HY-160040A

Cobitolimod sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
Cobitolimod sodium is a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory activity. Cobitolimod sodium inhibits Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .

HY-128353

ROR agonist-1	ROR	Inflammation/Immunology
ROR agonist-1 is a potent and orally bioavailable inverse agonist of the retinoic acid receptor-related orphan receptor C2 (RORC2), inhibition of IL-17A production from human primary T_H 17 cells with a pIC₅₀ of 7.5 .

HY-113238F

FITC-Lithocholic acid 3-sulfate FITC-Sulfolithocholic acid	Fluorescent Dye	Others
FITC-Lithocholic acid 3-sulfate (FITC-Sulfolithocholic acid) is a FITC-labeled Lithocholic acid 3-sulfate, which is a sulfated biliary metabolite. Lithocholic acid 3-sulfate selectively inhibits Th17 cell differentiation by targeting RORγt. Lithocholic acid 3-sulfate can be used for the research of pathogenesis of cholestatic liver diseases .

HY-142703

RORγt inverse agonist 28	ROR	Inflammation/Immunology
RORγt inverse agonist 28 is a potent reverse agonist of RORγt. RORγt inverse agonist 28 regulates the differentiation of Th17 cells and inhibits the production of IL-17. RORγt inverse agonist 28 has the potential for the research of inflammation and autoimmune diseases (extracted from patent WO2021228215A1, compound 6) .

HY-142806

RORγt inverse agonist 26	ROR	Inflammation/Immunology
RORγt inverse agonist 26 is a potent reverse agonist of RORγt. RORγt inverse agonist 26 regulates the differentiation of Th17 cells and inhibits the production of IL-17. RORγt inverse agonist 26 has the potential for the research of inflammation and autoimmune diseases (extracted from patent WO2021228215A1, compound 1) .

HY-142938

RORγt agonist 3	ROR	Inflammation/Immunology
RORγt agonist 3 is a potent agonist of RORγt. RORγt agonist 3 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 3 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136326A1, compound 23) .

HY-142937

RORγt agonist 2	ROR	Inflammation/Immunology
RORγt agonist 2 is a potent agonist of RORγt. RORγt agonist 2 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 2 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136339A1, compound 17) .

HY-155680

BET BD2-IN-1	Epigenetic Reader Domain	Inflammation/Immunology
BET BD2-IN-1 (compound 45) is a potent and selective inhibitor of BET BD2 (IC₅₀=1.6 nM). BET BD2-IN-1 inhibits the differentiation of Th17 cells by decreasing the activation of STAT3 and NF-κB. BET BD2-IN-1 is used in psoriasis and inflammatory bowel disease (IBD) research .

HY-112863

RORγt inhibitor 3	ROR	Inflammation/Immunology
RORγt inhibitor 3 is an orally active and potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitor. RORγt inhibitor 3 shows high binding affinity and inhibitory activity of Th17 cell differentiation. RORγt inhibitor 3 also shows efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models .

HY-120785A

SR1555 hydrochloride	ROR	Inflammation/Immunology
SR1555 hydrochloride is the hydrochloride salt form of SR1555 (HY-120785). SR1555 hydrochloride is an inverse agonist for retinoic acid receptor-related orphan nuclear receptor γ (RORγ) with an IC₅₀ of 1 μM. SR1555 hydrochloride inhibits the development and function of pro-inflammatory TH17 cell, increases the frequency of anti-inflammatory T regulatory (Treg) cells. SR1555 hydrochloride can be used for research about autoimmune diseases .

HY-125801R

3-Oxo-5β-cholanoic acid (Standard) Dehydrolithocholic acid (Standard); 3-oxoLCA (Standard)	Reference Standards ROR	Inflammation/Immunology
3-Oxo-5β-cholanoic acid (Standard) is the analytical standard of 3-Oxo-5β-cholanoic acid. This product is intended for research and analytical applications. 3-Oxo-5β-cholanoic acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (Kd=1.13 μM)[1].

HY-P10109A

G6PI 325-339 (human) hydrochloride hG6PI (325-339) hydrochloride	Glucose-6-Phosphate Isomerase (GPI)	Inflammation/Immunology
G6PI 325-339 (human) hydrochloride is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) hydrochloride primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) hydrochloride induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms .

HY-164455

AJI-214	STAT JAK Aurora Kinase Mitosis	Inflammation/Immunology
AJI-214 is a dual-target inhibitor of Aurora kinase A and JAK2. AJI-214 directly blocks Aurora kinase A to inhibit T cell mitotic progression and cell polarity, and inhibits JAK2 activation to inhibit STAT3 phosphorylation, thereby reducing the differentiation of TH1 and TH17 cells. AJI-214 can be used in studies on regulating immune responses and preventing graft-versus-host disease (GVHD) .

Cat. No.	Product Name	Type

HY-Y0344D

Sodium chloride, for cell culture

3 Publications Verification

Halite, for cell culture

Biochemical Assay Reagents

Sodium chloride, for cell culture is an orally active salt. Sodium chloride, for cell culture induces the expression of ATP1A1. Sodium chloride, for cell culture induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, for cell culture enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, for cell culture drives autoimmune disease by the induction of pathogenic Th17 cells .

HY-Y0344J

Sodium chloride, for molecular biology

3 Publications Verification

Halite, for molecular biology

Biochemical Assay Reagents

Sodium chloride is an orally active salt. Sodium chloride induces the expression of ATP1A1. Sodium chloride induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride drives autoimmune disease by the induction of pathogenic Th17 cells .

HY-Y0344I

Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al

3 Publications Verification

Halite, meets analytical specification of Ph. Eur. BP USP

Biochemical Assay Reagents

Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt is an orally active salt. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt induces the expression of ATP1A1. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt drives autoimmune disease by the induction of pathogenic Th17 cells .

HY-113238A

Lithocholic acid 3-sulfate disodium

Sulfolithocholic acid disodium; LCAS disodium

Biochemical Assay Reagents

Lithocholic acid 3-sulfate disodium is a GPR39 agonist, with EC₅₀ values of 41 μM and 42.4 μM in M39-20 and hGPR39-2 cells, respectively, in the absence of Zn ²⁺, and 0.88 μM and 0.97 μM in the presence of Zn ²⁺. Lithocholic acid 3-sulfate disodium acts as a RORγt ligand. Lithocholic acid 3-sulfate disodium stimulates the GPR39 receptor to initiate intracellular calcium signaling, independent of the Zn ²⁺-binding sites H17 and H19. LCA-3-S selectively inhibits Th17 cell differentiation by targeting RORγt. Lithocholic acid 3-sulfate disodium can be used in the research of cholestatic liver diseases .

HY-Y0344H

Sodium chloride, United States Pharmacopeia (USP) Reference Standard

Halite (Pharmaceutical primary standard, USP)

Biochemical Assay Reagents

Sodium chloride, United States Pharmacopeia (USP) Reference Standard is an orally active salt. Sodium chloride, United States Pharmacopeia (USP) Reference Standard induces the expression of ATP1A1. Sodium chloride, for cell culture induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, United States Pharmacopeia (USP) Reference Standard enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, United States Pharmacopeia (USP) Reference Standard drives autoimmune disease by the induction of pathogenic Th17 cells .

Cat. No.	Product Name	Target	Research Area

HY-P10109

G6PI 325-339 (human)	Glucose-6-Phosphate Isomerase (GPI)	Inflammation/Immunology
G6PI 325-339 (human) is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms .

HY-P10109A

G6PI 325-339 (human) hydrochloride hG6PI (325-339) hydrochloride	Glucose-6-Phosphate Isomerase (GPI)	Inflammation/Immunology
G6PI 325-339 (human) hydrochloride is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) hydrochloride primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) hydrochloride induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99256

Tildrakizumab SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody	Interleukin Related	Inflammation/Immunology Cancer
Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (K_d: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .

HY-P990145

Anti-Mouse VISTA Antibody (13F3)	VISTA	Inflammation/Immunology Cancer
Anti-Mouse VISTA Antibody (13F3) is an anti-mouse VISTA IgG monoclonal antibody. Anti-Mouse VISTA Antibody (13F3) can reverse the immunosuppressive effect of VISTA by blocking its binding to ligands such as VSIG3. Anti-Mouse VISTA Antibody (13F3) exacerbates pulmonary fibrosis (PF) by promoting Th17 cell differentiation. Anti-Mouse VISTA Antibody (13F3) can be used for research on cancer such as breast cancer and PF .

HY-P990796

Anti-Mouse IL-2 Antibody (S4B6-1)	Interleukin Related	Inflammation/Immunology Cancer
Anti-Mouse IL-2 Antibody (S4B6-1) is an anti-mouse IL-2 IgG2a monoclonal antibody. Anti-Mouse IL-2 Antibody (S4B6-1) can reduce CD4 ⁺ T cells and increase Tregs. Anti-Mouse IL-2 Antibody (S4B6-1) can induce Th17 cell differentiation. Anti-Mouse IL-2 Antibody (S4B6-1) can be used for research on cancer such as melanoma. The recommend isotype control of Anti-Mouse IL-2 Antibody (S4B6-1): Rat IgG2a kappa, Isotype Control (HY-P990679) .

HY-P991274

BMS-986010	Interleukin Related	Inflammation/Immunology
BMS-986010 is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). BMS-986010 reduces IL-23-induced STAT3 phosphorylation and inhibits Th17 cell differentiation and the release of proinflammatory cytokines (such as IL-17 and TNF-α). BMS-986010 is promising for research of autoimmune diseases such as psoriasis and Crohn's disease .

HY-P990177

Anti-Mouse Notch4 Antibody (HMN4-14)	Notch Influenza Virus	Infection Inflammation/Immunology
Anti-Mouse Notch4 Antibody (HMN4-14) is an anti-mouse Notch4 IgG monoclonal antibody. Anti-Mouse Notch4 Antibody (HMN4-14) reduces inflammation by restoring the expression of bispecific proteins. Anti-Mouse Notch4 Antibody (HMN4-14) can inhibit Th2/Th17 cell differentiation and improve Treg cell function. Anti-Mouse Notch4 Antibody (HMN4-14) can be used for research on inflammation conditions such as viral pneumonia and airway inflammation .

HY-P990252

Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2)	Notch Interleukin Related NF-κB VEGFR FGFR NO Synthase	Metabolic Disease Inflammation/Immunology Cancer
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is an anti-mouse Delta-like protein 4/DLL4 IgG monoclonal antibody. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce angiogenesis and density by blocking the DLL4-Notch signaling pathway. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) reduces inflammatory response by decreasing NF-κB activity and pro-inflammatory factors (IL-1β, iNOS, IL-6) levels. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can inhibit Th17 cell differentiation and *IL-17A* production. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce macrophage infiltration and alleviate insulin resistance. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can be used for researches on inflammation, metabolic conditions and cancer such as atherosclerosis, pancreatic cancer and asthma .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-145491

Resolvin D5	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	ERK NF-κB CCR
Resolvin D5 is an anti-inflammatory and analgesic agent produced in M2 macrophages. Resolvin D5 alleviates Paclitaxel (HY-B0015)-induced mechanical allodynia and inflammatory pain by activating the GPR32 receptor, with gender specificity (effective only in male mice) and independence from TRPV1 or TRPA1 channels. Resolvin D5 attenuates LPS-induced ERK phosphorylation and NF-κB nuclear translocation, downregulates proinflammatory mediators such as IL-6 and CCL5, inhibits Th17 cell differentiation and osteoclastogenesis, promotes regulatory T cell differentiation, and shows no cytotoxicity to human monocytes. The level of Resolvin D5 is elevated in arthritic SKG mice, but Resolvin D5 has no effect on dendritic cell differentiation or M1 macrophage polarization, nor does it prevent ZyA-induced arthritis progression. Resolvin D5 is suitable for research related to chemotherapy-induced peripheral neuropathy, inflammatory pain and rheumatoid arthritis .

HY-N0976

1,11b-Dihydro-11b-hydroxymedicarpin 11b-Hydroxy-11b,1-dihydromedicarpin	Structural Classification Natural Products Classification of Application Fields Leguminosae Derris robusta Plants Inflammation/Immunology Disease Research Fields Source Classification	Interleukin Related Wnt
1,11b-Dihydro-11b-hydroxymedicarpin (11b-Hydroxy-11b,1-dihydromedicarpin) is a pterocarpan from Ononis viscosa subsp. breviflora is a Medicarpin derivative . Medicarpin, a natural pterocarpan, heals cortical bone defect by activation of Notch and Wnt canonical signaling pathways . Medicarpin prevents arthritis in post-menopausal conditions by arresting the expansion of TH17 cells and pro-inflammatory cytokines. Medicarpin down-regulates pro-inflammatory cytokines like TNF-α, IL-6 and IL-17A, while up-regulates anti-inflammatory cytokine IL-10 in arthritis (CIA) model of mice .

HY-N16465

Cinnamtannin D1	Phenols Polyphenols Plants Lauraceae Lindera glauca (Siebold & Zucc.) Blume Source Classification	Apoptosis Reactive Oxygen Species (ROS) STAT
Cinnamtannin D1 is an orally active polyphenolic compound with immunosuppressive activity. Cinnamtannin D1 regulates the balance of Th17/Treg cells by inhibiting AHR expression. Cinnamtannin D1 reduces apoptosis and ROS in INS-1 cells and primary cultured murine islets induced by Palmitic acid (PA) (HY-N0830). Cinnamtannin D1 reduces Th17 cell differentiation via downregulating p-STAT3/RORγt and promotes Treg cell differentiation via upregulating p-STAT5/Foxp3. Cinnamtannin D1 exerts excellent anti-arthritic efficacy in collagen-induced arthritis (CIA) model of mice. Cinnamtannin D1 can be used for the study of rheumatoid arthritis (RA) .

Cat. No.	Product Name	Chemical Structure

HY-125801S

3-Oxo-5β-cholanoic acid-d4
3-Oxo-5β-cholanoic acid-d₄ (Dehydrolithocholic acid-d₄) is the deuterium labeled 3-Oxo-5β-cholanoic acid (HY-125801). 3-Oxo-5β-cholanoic acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (K_d=1.13 μM) .

Cat. No.	Product Name		Classification

HY-160040

Cobitolimod		Antisense Oligonucleotides
Cobitolimod is a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory activity. Cobitolimod suppresses Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .

HY-160040A

Cobitolimod sodium		Antisense Oligonucleotides
Cobitolimod sodium is a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory activity. Cobitolimod sodium inhibits Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

th17+cells

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products